• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Guanfacine ER for Adults With ADHD?

Guanfacine ER for Adults With ADHD?

October 6, 2020
Jesse Koskey, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jesse Koskey, MD. Dr. Koskey has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Iwanami A et al, J Clin Psychiatry 2020;81(3):19m12979

Study type: Randomized, double-blind, placebo-controlled trial

Stimulants are rapid, safe, and effective first-line treatments for many adults with ADHD. However, there are inevitably patients for whom stimulants are not indicated or tolerated—those with arrhythmias or stimulant use disorders, for example. Currently our only FDA-approved non-stimulant for adults with ADHD is atomoxetine (Strattera). The alpha-2A agonists—guanfacine ER (Intuniv) and clonidine ER (Kapvay)—are FDA approved for ADHD in children and adolescents but so far have lacked controlled trials in adult ADHD.

This 12-week, randomized, double-blind, placebo-controlled study of guanfacine ER was funded by Takeda, the manufacturer of Intuniv. It took place in 2016–2017 across several sites in Japan. Researchers randomly assigned 201 adults (average age 32, 65% male) with ADHD to either guanfacine ER or placebo. Half had combined ADHD, half had inattentive type, and very few (2%) had the hyperactive type. The dose of guanfacine ER was titrated over 5 weeks toward a target of 4–6 mg/day (average 5 mg/day), followed by a 5-week maintenance period and then a 2-week forced taper. The primary endpoint was overall symptom reduction by the Japanese-validated ADHD-RS-IV, a clinician-administered rating scale.

On average, participants who received guanfacine ER saw their ADHD scores drop from 31 (out of 54) to 20 points at the end of the treatment phase, compared to a drop from 31 to 24 for those receiving placebo. Improvements were similar for inattentive and hyperactive symptoms. This was statistically significant and corresponded to an effect size of 0.5 for guanfacine ER (similar to atomoxetine’s effect size in adults but smaller than the 0.7–0.9 effect size of stimulants). There were no significant reductions in either hyperactive symptoms or overall quality of life, although these were secondary endpoints.

A noteworthy 20% of patients receiving guanfacine ER discontinued treatment, with side effects including sedation, hypotension, and dizziness. It also caused a slight reduction in heart rate and prolongation of QTc relative to placebo, and in 2% of patients those EKG changes were still detectable 2 weeks after the medicine was stopped.

TCPR’s Take
Guanfacine ER appears to be a third-line drug for ADHD. It works, but is less effective than stimulants and not as well studied as atomoxetine. For healthy patients who cannot tolerate stimulants or have other reasons to avoid them, you might consider a trial of guanfacine—if atomoxetine is not helpful. Cost is not prohibitive with guanfacine ER, which went generic in 2015. Tolerability is the main drawback, and its cardiac effects may pose a problem in patients who are older or frailer than the ones enrolled in this study.


podcastsListen to our 10/26/20 podcast, “How to Use Guanfacine and Clonidine.” Search for “Carlat” on your podcast store.

General Psychiatry
KEYWORDS adhd alpha-agonists attention attention-deficit-hyperactivity-disorder guanfacine pharmacology psychopharmacology research-update
    Jesse Koskey, MD.

    Powering Up the Brain: tDCS for ADHD?

    More from this author
    www.thecarlatreport.com
    Issue Date: October 6, 2020
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Mood and Menopause, TCPR, October 2020
    Guanfacine ER for Adults With ADHD?
    Mood Stabilizers: What You Don’t Know Can Hurt Them
    Mood and Menopause
    Keeping Up With Trintellix
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.